Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This specimen collection lab protocol will allow the investigators to prospectively study immune reconstitution in patients being treated for hematologic disorders and immune factors affecting graft versus host disease in stem-cell transplant (SCT) patients.
Description: The rate of immune reconstitution in study participants treated for hematologic disorders and malignancies including SCT donors and recipients.
Measure: Rate of Immune Reconstitution in Study Participants Time: 1 yearDescription: Identification of the T cell subsets derived from samples from participants receiving stem cell therapy.
Measure: T cell subsets derived from samples for participants receiving stem cell therapy Time: 1 yearDescription: Immune status as determined via the examination of genomic profiles of responders vs non-responders to CAR-T therapy.
Measure: Immune status of responders and non-responders to CAR-T therapy Time: 1 yearAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports